The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Human epidermal growth factor receptor 2 (HER2)–directed antibody–drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally ...

Teclistamab, a T-cell engager targeting B-cell maturation antigen, showed promise as a rescue therapy in 10 patients with refractory autoimmune diseases and led to clinical and serologic improvemen ...

A 43-year-old woman with bipolar disorder and advanced HIV infection was admitted to this hospital because of depressed mood, suicidal ideation, cough, and a temperature of 39.5°C. A diagnosis was ...

A new FDA program is being promoted as a tool to facilitate the development and approval of therapies that are important for society. But it risks undermining regulatory innovation and trust in ...